Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin
Open Access
- 24 February 2020
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 45 (6) , 990-997
Abstract
Twenty-four hours after administration, ketamine exerts rapid and robust antidepressant effects that are thought to be mediated by activation of the mechanistic target of rapamycin complex 1 (mTORC1). To test this hypothesis, depressed patients were pretreated with rapamycin, an mTORC1 inhibitor, prior to receiving ketamine. Twenty patients suffering a major depressive episode were randomized to pretreatment with oral rapamycin (6 mg) or placebo 2 h prior to the intravenous administration of ketamine 0.5 mg/kg in a double-blind cross-over design with treatment days separated by at least 2 weeks. Depression severity was assessed using Montgomery–Åsberg Depression Rating Scale (MADRS). Rapamycin pretreatment did not alter the antidepressant effects of ketamine at the 24-h timepoint. Over the subsequent 2-weeks, we found a significant treatment by time interaction (F(8,245) = 2.02, p = 0.04), suggesting a prolongation of the antidepressant effects of ketamine by rapamycin. Two weeks following ketamine administration, we found higher response (41%) and remission rates (29%) following rapamycin + ketamine compared to placebo + ketamine (13%, p = 0.04, and 7%, p = 0.003, respectively). In summary, single dose rapamycin pretreatment failed to block the antidepressant effects of ketamine, but it prolonged ketamine’s antidepressant effects. This observation raises questions about the role of systemic vs. local blockade of mTORC1 in the antidepressant effects of ketamine, provides preliminary evidence that rapamycin may extend the benefits of ketamine, and thereby potentially sheds light on mechanisms that contribute to depression relapse after ketamine administration.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH101498)
- U.S. Department of Veterans Affairs (NA)
This publication has 46 references indexed in Scilit:
- Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming testUpsala Journal of Medical Sciences, 2012
- Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On TrialBiological Psychiatry, 2012
- Lifelong rapamycin administration ameliorates age‐dependent cognitive deficits by reducing IL‐1β and enhancing NMDA signalingAging Cell, 2011
- NMDA receptor blockade at rest triggers rapid behavioural antidepressant responsesNature, 2011
- Glutamate N-methyl-D-aspartate Receptor Antagonists Rapidly Reverse Behavioral and Synaptic Deficits Caused by Chronic Stress ExposureBiological Psychiatry, 2011
- mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA AntagonistsScience, 2010
- A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar DepressionArchives of General Psychiatry, 2010
- Immunoregulatory functions of mTOR inhibitionNature Reviews Immunology, 2009
- Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient GlioblastomaPLOS Medicine, 2008
- Clinical Pharmacokinetics of SirolimusClinical Pharmacokinetics, 2001